Search LEHREN

WHO: Trial of hydroxychloroquine for COVID-19 treatment to resume

WHO chief Tedros Ghebreyesus today said that the trial of hydroxychloroquine for treatment of coronavirus will resume. "On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol," he said.

4th June 2020 | 12:49 PM (IST)
66 views

The World Health Organization announced Wednesday that clinical trials of the drug hydroxychloroquine will resume as it searches for potential coronavirus treatments.

On May 25, the WHO announced it had temporarily suspended the trials to conduct a safety review, which has now concluded there is "no reason" to change the way the trials are conducted.

 

The UN health agency's decision came after a study published in The Lancet medical journal suggesting the drug could increase the risk of death among COVID-19 patients.

 

The executive group of the so-called Solidarity Trial -- in which hundreds of hospitals across the world have enrolled patients to test several possible treatments for the novel coronavirus -- took the decision as a precaution.

Anti-Malaria Drug Hydroxychloroquine's Coronavirus Trials To Resume: WHO

World Health Organization had earlier temporarily suspended trials of the drug (File)

The World Health Organization announced Wednesday that clinical trials of the drug hydroxychloroquine will resume as it searches for potential Coronavirus treatments.

On May 25, the WHO announced it had temporarily suspended the trials to conduct a safety review, which has now concluded there is "no reason" to change the way the trials are conducted. 

The UN health agency's decision came after a study published in The Lancet medical journal suggesting the drug could increase the risk of death among COVID-19 patients.

 Must Read  PM Modi not in 'good mood' over 'big conflict' between India and China

The executive group of the so-called Solidarity Trial -- in which hundreds of hospitals across the world have enrolled patients to test several possible treatments for the novel coronavirus -- took the decision as a precaution.

WHO pauses hydroxychloroquine trial over safety concerns. 

The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday. Gavino Garay has more.

Hydroxychloroquine is normally used to treat arthritis but public figures including US President Donald Trump have backed the drug for COVID-19 prevention and treatment, prompting governments to bulk-buy.

"Last week, the executive group of the Solidarity Trial decided to implement a temporary pause of the hydroxychloroquine arm of the trial, because of concerns raised about the safety of the drug," WHO chief Tedros Adhanom Ghebreyesus told a virtual news briefing.

"This decision was taken as a precaution while the safety data were reviewed."

"The data safety and monitoring committee of the Solidarity Trial has been reviewing the data."

"On the basis of the available mortality data, the members of the committee recommended that there are no reasons to modify the trial protocol."

 Also Read  US will consider rejoining WHO if it ends corruption, reliance on China

"The executive group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine."

"The executive group will communicate with the principal investigators in the trial about resuming the Hydroxychloroquine arm of the trial."

"The data safety and monitoring committee will continue to closely monitor the safety of all therapeutics being tested in the Solidarity Trial."

More than 3,500 Patients have been recruited across 35 countries to take part in the trials.

Download The Lehren App For Latest & More News, Gossips, Videos And Podcasts.

4th June 2020 | 12:49 PM (IST)
66 views
×
×